The Canadian Government has granted permission to a startup for exporting psychedelic substances to Australia for medicinal purposes. Optimi Health Corp. is now responsible for sending pills laced with psilocybin, an extract from magic mushrooms, and MDMA, under the approval of the health department.
The growing demand is not limited to magic mushrooms in Ontario anymore. Other countries have begun to follow Canada’s example, exploring and legalizing the use of serotonergic compounds for medical applications.
Rest assured, you can buy psychedelics online in Canada and tap into your innate potential through trustworthy sources.
[toc]Key Takeaways:
- Vancouver-based startup, Optimi Health, has been given a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment comprises of three sessions, each around eight hours long, spread over a period of five to eight weeks.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain a first-mover advantage.
A total of seven companies have exported psilocybin, MDMA, or both, but only for clinical trial purposes. A representative from Canada’s health department could not confirm if these exports were for regular patient use and declined to reveal the companies due to security reasons.
With this accomplishment, Optimi joins a select group of global suppliers, with the current market skewing towards clinical rather than recreational use.
What’s in the Pill?
Although the company hasn’t disclosed the specific mushroom strain used in the pill, they are known to work with various strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, examine, and extract its psychedelic mushrooms. This quaint town, home to about 3,000 people, is situated three hours to the east of Vancouver.
Australia’s Relationship With Psychedelic Mushrooms
Statistics indicate that 1 in 5 Australians, aged between 16 and 85, might contend with mental illness. PTSD (post-traumatic stress disorder) could impact 11% of Australians at some stage in their lives, while anxiety disorders are experienced by 17% of the populace.
While there’s a wide spectrum of therapies to manage mental health conditions, not all are effective for every individual. Finding a beneficial treatment can be a daunting task for patients unresponsive to specific therapies, increasing their susceptibility to mental health issues.
The Procedure Unveiled
Australia has been a trailblazer in the utilization of psilocybin, allowing authorized psychiatrists to employ this regulated substance in treating PTSD and therapy-resistant depression.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and shrooms for therapeutic application. The TGA asserted that these substances are safe when used in a medically supervised setting for patients with severe mental disorders.
This advancement has been groundbreaking for numerous mental health professionals and researchers. The consumption of these substances will be strictly monitored; it’s not as simple as taking a pill and departing.
The treatment regimen typically comprises three sessions over a span of five to eight weeks. Each session lasts around eight hours, with the therapist present with the patient throughout.
Canada’s Role in Psilocybin Research
Canada has become a significant center for psilocybin research, greatly augmenting our understanding of this compound. Health Canada, in collaboration with various institutions, is leading the investigation into psilocybin’s therapeutic potential for treating diverse mental health conditions.
Research institutions are no longer required to consider these substances illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to grow shrooms for research purposes.
This newfound access to substances once deemed harmful enables researchers to advance their understanding of their potential benefits to a wide array of individuals.
A Recurrent Trend
The potential of this discipline was first acknowledged in the 1950s for its potential to tackle mental health disorders and substance dependency, including alcoholism. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneers in this early exploration at the Saskatchewan Mental Hospital in Weyburn. Under the leadership of then-premier Tommy Douglas, the medical community was granted substantial freedom to investigate their medical hypotheses, resulting in notable progress.
Dr. Osmond and Dr. Hoffer initiated research with LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their exploration took unanticipated turns, with the pair advocating for medical professionals, nurses, and support staff to experiment with these substances.
Research at Canadian Health Institutes
Through its Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is sponsoring three clinical studies to assess the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress at end-of-life in patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This investment in research will contribute to a better understanding of the advantages of controlled substances. This has been made possible by the Canadian Drugs and Substances Strategy (CDSS), a program launched by the Government of Canada.
Further Psychedelic Studies
Vancouver psychiatrists have started a phase III clinical trial of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The therapy includes three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. Researchers consider this trial to be historically important as it marks the first clinical exploration of an illegal psychedelic substance in over four decades.
Getting to Know Psilocybin
Psilocybin is a naturally prevailing psychedelic compound that can be found in certain mushroom species. Upon consumption, it metabolizes into psilocin, which stimulates the serotonin 5-HT2a receptors located on the cortical pyramidal cells in the brain, recognized as the central processing sites.
Local authorities are currently investigating the substance for its potential to help with depression, anxiety, addiction, and end-of-life distress by encouraging introspection and spiritual enlightenment.
Why is it Potentially Effective Against Depression, PTSD, and More?
The active ingredient targets multiple brain areas, making it potentially beneficial for a range of mental conditions. Numerous patients in Canada and Australia have been treated using this therapy and reported positive outcomes, with minor side effects such as temporary anxiety or increased blood pressure.
Neurobiological Effects
- Serotonin Receptor Activation: The substance acts as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, playing a crucial role in emotional processing and mood regulation.
- Default Mode Network (DMN) Modulation: The substance reduces activity in the DMN, promoting introspection, diminishing rigid thought processes, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the substance are due to its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressive states, individuals often show reduced responsiveness to emotional stimuli. The substance enhances the response to positive emotional stimuli in the right amygdala and lowers or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: Promotes feelings of happiness, interconnectedness, and emotional transparency during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience potentially allows individuals to safely face and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that it can result in enduring positive changes such as better overall well-being, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Shops?
Ever wondered how this substance might affect your mental health? Explore your local magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, encourages creative thinking, and promotes productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Supports enhanced wellness and improves overall life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Spurs clarity, creativity, and focus. Comes with a robust blend of clinical-strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Worldwide Acknowledgement of Psilocybin
Canada is not the only country supporting the use of magic mushrooms for mental health problems. Other countries like Australia are also embracing these hallucinogens to tackle conditions such as depression and PTSD. They are procuring top-grade psychedelic capsules from trustworthy sources. Under proper guidance, patients can significantly improve their life quality. Shrooms Near Me Canada, a magic mushroom supplier, offers a variety of products, from capsules to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA hold therapeutic value by enhancing mental well-being. Psilocybin interacts with serotonin 2A receptors and proves beneficial for treating depression and addiction.
Conversely, MDMA promotes empathy and proves effective in PTSD treatment. It shows promise in improving emotional processing and
Despite its classification as a controlled substance, it has been found to yield therapeutic results.
Is this treatment option accessible to all Australians?
No. In Australia, an individual’s eligibility to use the substance is determined after a thorough evaluation. This assessment takes into account factors such as pre-existing heart conditions and a history of psychosis, among other things. Only patients who have not responded to conventional treatments for conditions like depression, anxiety, or PTSD can access this treatment.
What are the implications of Canada’s mushroom exports?
Canada is strategically positioning itself to lead the psychedelics market, mirroring its approach to cannabis. This would enable more companies to produce high-quality products. As a result, Canada could become a leader in the hallucinogen market, strengthen its economy, and make these treatments more accessible for other countries. It would also discourage countries from procuring their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles That Might Pique Your Interest:
